Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
| Registry | NCT07166315 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 700 (Estimated) |
| Sponsor | Adelphi Real World (Industry) |
| Conditions | Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA) |
| Interventions | observational study (Other) |
| Dates | start 2025-07-07, primary completion 2027-07-31 (estimated), completion 2027-07-31 (estimated), first posted 2025-09-10, last updated 2026-10-27 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Axial Spondylarthritis (axSpA) All trials for Psoriatic Arthritis (PsA) All trials of observational study
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Axial spondyloarthritis (axSpA) | Other: observational study | Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor. | |
| Psoriatic arthritis (PsA) | Other: observational study | Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). * Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. * Participant is aged 18 years or older at enrolment. Exclusion Criteria: -Participation in a clinical trial at enrolment.
| Facility | City | Country | Status |
|---|---|---|---|
| Royal National Hospital for Rheumatic Diseases | Bath, Somerset | United Kingdom | Recruiting |